AzTrials
AzTrials

Type 1 DiabetesADHERENCENCT01580462

The ADHERENCE Index - the Indicator of Effective Coping With the Requirements of the Disease of Children and Adolescents With Type 1 Diabetes

An observational study of Type 1 Diabetes, run by Institute of Mother and Child, Warsaw, Poland at 1 site in Poland.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of the research is to develop a mathematical model called ADHERENCE index, and to evaluate its effectiveness. Read more about this study

Who is it for?
Ages Up to 18 years
Conditions the study is for
Type 1 Diabetes
What is being tested?
Observational study
How many people
200 participants
Where
1 sitePoland
Study dates
Apr 2012to Oct 2012
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: Participants will be recruited from the Outpatient Diabetes Clinic in the Institute of Mother and Child. Patient should be treated by intensive insulinotherapy using Continous Subcutaneus Infusion Set (CSII). Number of participants: 200.

Who may be able to join

  • type 1 diabetes for min. 1 year
  • CSII
  • ability to come for one additional visit in outpatient diabetes clinic
  • using glucometers

Who cannot join

  • no possibility to download data from patient's glucometer and insulin pump

Trial locations and contacts

1 site in 1 country.

Katarzyna A Gajewska, MSc contact

48223277105

katarzyna.gajewska@imid.med.pl

Poland1 site, 1 recruiting
  • Outpatient Diabetes Clinic of the Institute of Mother and Child

    Warsaw, Masovian Voivodeship, 01-211

    Katarzyna A Gajewska, MSc

    Recruiting

Other trials in Poland

About this study

Official title: The ADHERENCE Index - the Indicator of Effective Coping With the Requirements of the Disease of Children and Adolescents With Type 1 Diabetes. Prospective Study

The aim of the research is to develop a mathematical model called ADHERENCE index, and to evaluate its effectiveness.

Read the detailed description

For many years glycosylated hemoglobin A1C is one of the universal indicators of metabolic control in patients with diabetes. The results of A1C levels reflect the average blood glucose levels from the period of three months. A1C is one of the most important information for diabetes team, it allows to determine the effects of treatment. In the long-term analysis, it is a predictor of the complication risk. A1C value is affected by many factors: the method of treatment, type of insulin, self-control, numbers of hypoglycemia etc. In the case of similar methods of treatment, ability to cope with diabetes self-management, ability of correct interpretation of glycemic values and adaptation of insulin doses appears to be the factor, which determines A1C levels. But, there is still a lack of objective methods to assess effective coping with the requirements of the illness - adherence. Currently it is based primarily on a subjective feeling of diabetes team.

The aim of the research is to develop a mathematical model called ADHERENCE index, and to evaluate its effectiveness.

Methods

Participants:

Participants will be recruited from the Outpatient Diabetes Clinic in the Institute of Mother and Child. Patient should be treated by intensive insulinotherapy using Continuous Subcutaneous Infusion Set (CSII). Number of participants: 200.

Study plan - data collecting:

Patients will attend diabetes clinic as usual, with one additional visit in the middle of the 3-months period. During those visits, data from glucometers and insulin pumps will be downloaded.

  1. Visit 1 (V0) - getting agreement to participate in the study, giving information about the study, collecting patient's in initial interview. HbA1c measurement by DCA Vantage Analyzer (Siemens), control the settings of time and date in insulin pumps and glucometer(s), ask for using one kind of glucometer, and if it's impossible - to set time and date in every glucometer, and to take them all for the next visits. Setting terms of next visits (after 6 ±1 and 12 ±2 weeks)
  2. Visit 2 (V1) - after 6 ±1 weeks after V0 - downloading data from the insulin pump and glucometer(s) by Diasend and CareLink software. Collecting information about some accidents: ketoacidosis, severe hypoglycemia, ketonuria, illness treated with antibiotics. Reminding about the next visit (V2).
  3. Visit 3 (V2) - after 6 ±1 weeks after V1 - the last visit; downloading data from the insulin pump and glucometer(s) by Diasend and CareLink software. Collecting information about some accidents: ketoacidosis, severe hypoglycemia, ketonuria, illness treated with antibiotics; the A1C measurement.

After data collection they will be taken under analysis. Downloaded data will be compared to A1C. After that, factors, which are crucial for A1C will be found. Last part of the research is an attempt to create a mathematical model.

Data important for mathematical model:

Downloaded:

BG values - average, standard deviation, number of values per day, values above goal (>180 mg/dl), values within goal (70-180 mg/dl), values below goal (<70 mg/dl), percentage of measurements fall within the recommended range (70-180 mg/dl); Low Blood Glucose Index (LBGI) and High Blood Glucose Index (HBGI).

Insulin pumps data - average total daily dose, average daily basal, average daily bolus, percentage of daily basal and bolus doses, number of boluses per day, number of extended boluses per day, using of temporary basal rate, number of stoppings, number of days with one infusion set.

Collected by the interview:

Number and time of ketoacidosis, ketonuria, severe hypoglycemia, illness treated with antibiotics. Interview during the V0 visit: sex, weight, height, age, suffering from diabetes in age, A1C level, reported total daily dose, type of insulin (Humalog, Novorapid, Apidra), number of places in body for infusion, reported number of days with one infusion set, place of residence (village, town, city).

Expected outcomes

Obtaining a mathematical model - an ADHERENCE index - will allow to assess an adherence to diabetes and self-management. It will be an objective indicator, which could allow to identify the most impacting factor which determines A1C levels and to identify this aspects of diabetes self- management, which should be improved by diabetes education or motivation. Using of ADHERENCE index should allow to identify patients with poor self-management earlier, than it could be symbolized by high A1C level. It could also allow to draw conclusions about the most important aspects of diabetes self-management.

Conditions
Type 1 Diabetes
Being tested
Observational study
Keywords
continuous subcutaneous insulin infusion (CSII), children, adolescent
Medical subject headings
Diabetes Mellitus, Type 1

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Observational studyOther

    Study plan - data collecting:

    Patients will attend diabetes clinic as usual, with one additional visit in the middle of the 3-months period. During those visits - V0, V1 and V2, data from glucometers and insulin pumps will be downloaded.

Study groups in NCT01580462
Study groupRoleWhat they receive
Children and Adolescent with type 1 diabetes on CSIINot described
Receives: Other: Observational study

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Apr 2012 (estimated)
  2. Study startApr 2012
  3. Primary completionJun 2012 (estimated)
  4. Study completionOct 2012 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Time perspective
Prospective
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01580462
Sponsor's protocol ID
OPK 510-13-55
Acronym
ADHERENCE
Status last verified
Apr 2012
First submitted
18 Apr 2012
Last updated
19 Apr 2012
Results posted
No

Questions about this trial

What is this clinical trial studying?

An observational study of Type 1 Diabetes, run by Institute of Mother and Child, Warsaw, Poland at 1 site in Poland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Apr 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Katarzyna A Gajewska, MSc (48223277105, katarzyna.gajewska@imid.med.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Apr 2012.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in